366 related articles for article (PubMed ID: 16792600)
1. Immunological mechanisms of sublingual immunotherapy.
Akdis CA; Barlan IB; Bahceciler N; Akdis M
Allergy; 2006; 61 Suppl 81():11-4. PubMed ID: 16792600
[TBL] [Abstract][Full Text] [Related]
2. Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation.
Bohle B; Kinaciyan T; Gerstmayr M; Radakovics A; Jahn-Schmid B; Ebner C
J Allergy Clin Immunol; 2007 Sep; 120(3):707-13. PubMed ID: 17681368
[TBL] [Abstract][Full Text] [Related]
3. Immune mechanisms of allergen-specific sublingual immunotherapy.
Moingeon P; Batard T; Fadel R; Frati F; Sieber J; Van Overtvelt L
Allergy; 2006 Feb; 61(2):151-65. PubMed ID: 16409190
[TBL] [Abstract][Full Text] [Related]
4. Dendritic cells as potential targets for mucosal immunotherapy.
Allam JP; Bieber T; Novak N
Curr Opin Allergy Clin Immunol; 2009 Dec; 9(6):554-7. PubMed ID: 19745726
[TBL] [Abstract][Full Text] [Related]
5. An immunological overview of allergen specific immunotherapy -- subcutaneous and sublingual routes.
Ozdemir C
Ther Adv Respir Dis; 2009 Oct; 3(5):253-62. PubMed ID: 19880430
[TBL] [Abstract][Full Text] [Related]
6. Recent progress in allergen immunotherapy.
Nouri-Aria KT
Iran J Immunol; 2008 Mar; 5(1):1-24. PubMed ID: 18319521
[TBL] [Abstract][Full Text] [Related]
7. Immunological mechanisms of sublingual allergen-specific immunotherapy.
Novak N; Bieber T; Allam JP
Allergy; 2011 Jun; 66(6):733-9. PubMed ID: 21251016
[TBL] [Abstract][Full Text] [Related]
8. Scientific rationale for the Finnish Allergy Programme 2008-2018: emphasis on prevention and endorsing tolerance.
von Hertzen LC; Savolainen J; Hannuksela M; Klaukka T; Lauerma A; Mäkelä MJ; Pekkanen J; Pietinalho A; Vaarala O; Valovirta E; Vartiainen E; Haahtela T
Allergy; 2009 May; 64(5):678-701. PubMed ID: 19383025
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of sublingual immunotherapy.
Scadding G; Durham S
J Asthma; 2009 May; 46(4):322-34. PubMed ID: 19484663
[TBL] [Abstract][Full Text] [Related]
10. Sublingual immunotherapy in the treatment of children.
Pham-Thi N; de Blic J; Scheinmann P
Allergy; 2006; 61 Suppl 81():7-10. PubMed ID: 16792599
[TBL] [Abstract][Full Text] [Related]
11. Local immunological mechanisms of sublingual immunotherapy.
Allam JP; Novak N
Curr Opin Allergy Clin Immunol; 2011 Dec; 11(6):571-8. PubMed ID: 22001742
[TBL] [Abstract][Full Text] [Related]
12. Sublingual immunotherapy mechanisms of action: the role of Th1 response.
Ciprandi G; Tosca MA; Marseglia GL
Int J Immunopathol Pharmacol; 2009; 22(4 Suppl):9-12. PubMed ID: 19944003
[TBL] [Abstract][Full Text] [Related]
13. Two year follow-up of immunological response in mite-allergic children treated with sublingual immunotherapy. Comparison with subcutaneous administration.
Antúnez C; Mayorga C; Corzo JL; Jurado A; Torres MJ
Pediatr Allergy Immunol; 2008 May; 19(3):210-8. PubMed ID: 18399897
[TBL] [Abstract][Full Text] [Related]
14. Sublingual immunotherapy reduces allergic symptoms in a mouse model of rhinitis.
Brimnes J; Kildsgaard J; Jacobi H; Lund K
Clin Exp Allergy; 2007 Apr; 37(4):488-97. PubMed ID: 17430344
[TBL] [Abstract][Full Text] [Related]
15. Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile.
Calderón MA; Simons FE; Malling HJ; Lockey RF; Moingeon P; Demoly P
Allergy; 2012 Mar; 67(3):302-11. PubMed ID: 22150126
[TBL] [Abstract][Full Text] [Related]
16. Allergen-related approaches to immunotherapy.
Rolland JM; Gardner LM; O'Hehir RE
Pharmacol Ther; 2009 Mar; 121(3):273-84. PubMed ID: 19111571
[TBL] [Abstract][Full Text] [Related]
17. Subcutaneous versus sublingual immunotherapy for allergic rhinitis and/or asthma.
Bahceciler NN; Cobanoglu N
Immunotherapy; 2011 Jun; 3(6):747-56. PubMed ID: 21668312
[TBL] [Abstract][Full Text] [Related]
18. Allergen immunotherapy.
Frew AJ
J Allergy Clin Immunol; 2010 Feb; 125(2 Suppl 2):S306-13. PubMed ID: 20176266
[TBL] [Abstract][Full Text] [Related]
19. Age and indications to SLIT.
Terracciano L; Calcinai E; Avitabile S; Galli E
Int J Immunopathol Pharmacol; 2009; 22(4 Suppl):5-8. PubMed ID: 19944002
[TBL] [Abstract][Full Text] [Related]
20. Phl p 5 resorption in human oral mucosa leads to dose-dependent and time-dependent allergen binding by oral mucosal Langerhans cells, attenuates their maturation, and enhances their migratory and TGF-beta1 and IL-10-producing properties.
Allam JP; Würtzen PA; Reinartz M; Winter J; Vrtala S; Chen KW; Valenta R; Wenghoefer M; Appel T; Gros E; Niederhagen B; Bieber T; Lund K; Novak N
J Allergy Clin Immunol; 2010 Sep; 126(3):638-45.e1. PubMed ID: 20584546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
